Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Safety profile and to determine maximum tolerated dose of Sorafenib in combination with
Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent